MEK/ERK inhibitors may become a new type of drug for the treatment of Ems.32–34 Simon et al35 found in oral cancer research that the MEK/ERK pathway is activated in oral cancer cells. This evidence concerns the gene MAP2K7 and lip and oral cavity carcinoma.